Overview
OCGN market data
Price History
OCGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.23 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,343.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.98 – $2.73 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $457.8M · P/B 7.91 · P/S 95.91.
Company News
8-K filing — Ocugen, Inc. (OCGN)SEC EDGAR · Aug 6, 2026, 12:30 PM
Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K EstimateBenzinga · Aug 6, 2026, 11:03 AM
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular DegenerationBenzinga · Jul 29, 2026, 11:12 AM
Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North AfricaBenzinga · Jul 13, 2026, 11:16 AM
Ocugen to Participate in Upcoming July Industry ConferencesGlobenewswire Inc · Jul 1, 2026, 11:15 AM
Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11Benzinga · May 27, 2026, 12:51 PM